9/28/26
Samil Pharmaceutical Co.,Ltd (000520.KS) Thesis The ongoing decline in net income and operating cash flow, coupled with increased pricing pressures, has led to a more negative outlook on the company's financial health.
★ Analysts see FY2027 revenue reaching $267.0B — +13.6% growth in a single year.
What Could Go Wrong 01 Increased pricing pressure from competitors has led to a 15% decline in generic drug prices, impacting margins significantly. 02 Operating cash flow has turned negative, indicating potential liquidity issues if not addressed promptly. 03 Regulatory changes impacting drug approval processes 04 Technological disruption in drug manufacturing and delivery 05 Intense competition from both local and international generic manufacturers 06 Potential for price wars in the generic drug market 07 High debt levels could strain liquidity, especially with negative cash flow 08 Potential pension obligations impacting financial stability 5226 6733 8240 9747 11254 8100 000520.KS Daily 8100.00 May '26 Jun '26 Aug '26 Sep '26
My Notes "Management has acknowledged the challenges posed by competitive pricing and cash flow pressures." Moat: Samil's competitive advantage lies in its established market presence and strong R&D capabilities… Watch: The rise of biosimilars and advanced therapeutics poses a significant threat to traditional generic drug manufacturers. value - Investors may be attracted to the low price-to-sales ratio of 0.7x, indicating potential undervaluation. Interest rates affect Samil's financing costs for R&D and capital expenditures, which are critical for growth. Watch on earnings: Generic drug pricing trends, Regulatory approval timelines for new drugs, Market share in oncology and cardiovascular segments. One Sentence Summary: The bear case: increased pricing pressure from competitors has led to a 15% decline in generic drug prices, impacting margins significantly.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
